Table of Contents
1
UI - 11464132
AU - Seseke F; Zoller G; Kunze E
TI -
Clear cell adenocarcinoma of the male urethra in association with
so-called nephrogenic metaplasia.
SO - Urol Int 2001;67(1):104-8
AD - Departments of Urology and Pathology, University of Gottingen, Germany.
fseseke@gwdg.de
A clear cell adenocarcinoma of the urethra associated with so-called
nephrogenic metaplasia occurring in a 57-year-old male patient is
presented. Ten months following total urethrectomy, multiple pulmonary
metastases had developed. The patient died 2.5 years after surgery. The
possible histogenesis of clear cell adenocarcinoma of the lower urinary
tract - reported to develop in the male urethra only in a very few cases
- is reviewed briefly. We favor an origin from preexisting nephrogenic
metaplasia as one of the possible histogenetic pathways. Copyright 2001
S. Karger AG, Basel
2
UI - 11490207
AU - Koga F; Nagamatsu H; Ishimaru H; Mizuo T; Yoshida K
TI -
Risk factors for the development of bladder transitional cell carcinoma
following surgery for transitional cell carcinoma of the upper urinary
tract.
SO - Urol Int 2001;67(2):135-41
AD - Department of Urology, Tokyo Rosai Hospital, Tokyo, Japan.
f-koga@wine.plala.or.jp
To determine the risk factors for development of transitional cell
carcinoma (TCC) of the bladder (BTCC) following surgery for TCC of the
upper urinary tract (UUT-TCC) in patients without history of BTCC, 85
patients surgically treated for UUT-TCC (34 female, 51 male; median age
66, range 42-85 years) were reviewed retrospectively. The Cox
proportional hazards model was used to assess the association of
relevant clinicopathologic factors with BTCC-free survival in patients
without a history of BTCC and TCC-specific survival in all. Median
follow-up duration was 35 (range 1-193) months. Six patients (7%) had
previous histories of BTCC, and 6 others (7%) had concurrent BTCC at the
time of surgery for UUT-TCC. Of 70 patients who had no history of BTCC
and underwent follow-up cystoscopy, 24 (34%) developed BTCC during
follow-up after surgery. Univariate analysis identified female sex,
postoperative systemic chemotherapy, and incomplete distal ureterectomy
as significant risk factors for new development of BTCC. After
multivariate analysis adjusted for age and pathological (p) T stage in
the TNM classification, all three factors remained significant, with
respective hazard ratios of 5.56 (95% confidence interval (CI),
1.99-15.6; p = 0.001), 3.19 (95% CI, 1.34-7.62; p = 0.009) and 2.99 (95%
CI, 1.08-8.26; p = 0.03). Only pT stage was a significant independent
risk factor for TCC-specific death. Female sex and postoperative
systemic chemotherapy, as well as incomplete distal ureterectomy, are
possible riks factors for development of BTCC following surgery for
UUT-TCC. Copyright 2001 S. Karger AG, Basel
3
UI - 11490218
AU - Er O; Coskun HS; Altinbas M; Akgun H; Cetin M; Eser B; Unal A
TI -
Rapidly relapsing squamous cell carcinoma of the renal pelvis associated
with paraneoplastic syndromes of leukocytosis, thrombocytosis and
hypercalcemia.
SO - Urol Int 2001;67(2):175-7
AD - Department of Medical Oncology, Erciyes University Medical Faculty,
Kayseri, Turkey. oz_er_99@yahoo.com
A case history is reported here in which leukocytosis, thrombocytosis
and hypercalcemia associated with rapidly relapsing squamous cell
carcinoma (SCC) of the renal pelvis were observed. In a 58-year-old man,
SCC of the renal pelvis was documented during nephrolithotomy, and right
nephrectomy was performed. Local relapse of the tumor occurred rapidly
in 2 months' time and hypercalcemia, leukocytosis and thrombocytosis
worsened in accordance with tumor volume. Cranial computerized
tomography (CT), thorax CT and bone scintigraphy were negative for
metastasis. The serum parathyroid hormone level was 28 pg/ml (normal 9-
55 pg/ml). To disclose leukocytosis and thrombocytosis, peripheral smear
and bone marrow aspiration were performed and no pathologic finding
regarding any hematologic disorder was found; the samples were also
BCR-ABL negative and Philadelphia chromosome negative. Production of
several factors by tumor cells may be responsible for this
paraneoplastic syndrome. The association of SCC of the renal pelvis with
this triple paraneoplastic syndrome is an extremely rare occurrence.
Copyright 2001 S. Karger AG, Basel.
4
UI - 11796281
AU - Irie A; Iwamura M; Kadowaki K; Ohkawa A; Uchida T; Baba S
TI -
Intravesical instillation of bacille Calmette-Guerin for carcinoma in
situ of the urothelium involving the upper urinary tract using
vesicoureteral reflux created by a double-pigtail catheter.
SO - Urology 2002 Jan;59(1):53-7
AD - Department of Urology, Kitasato University School of Medicine, Kanagawa,
Japan.
OBJECTIVES: To evaluate the therapeutic efficacy of bacille
Calmette-Guerin (BCG) for carcinoma in situ (CIS) of the urothelium
involving the upper urinary tract when the vaccine was administered by
way of the bladder using vesicoureteral reflux created by a
double-pigtail (DP) catheter. METHODS: Thirteen upper urinary tracts of
9 patients with cytologically diagnosed CIS, with concomitant bladder
CIS in 4, were treated by intravesical BCG instillation. A DP catheter
was placed retrogradely, and the appearance of vesicoureteral reflux was
confirmed by cystography. BCG (1 to 2 mg/mL) in a volume sufficient to
fill the renal caliceal system was administered into the bladder weekly
for 6 weeks. The mean follow-up was 36 months (range 8 to 97). RESULTS:
The voided urine cytology turned negative in all 9 patients at a mean of
86 days after the first administration of BCG. The voided urine cytology
returned positive afterward in 3 patients, and positive cytology in the
upper urinary tract was confirmed in 1 of 13 treated urinary tracts,
which were successfully treated by another course of BCG therapy with
the DP catheter. Minor adverse effects related to BCG and the DP
catheter were seen in 5 patients. CONCLUSIONS: BCG therapy for the CIS
involving the upper urinary tract using a DP catheter might have the
potential to be an effective procedure preserving renal units and could
be adopted not only as an imperative, but also as an elective, treatment
option.
5
UI - 11821513
AU - Bazari H; Mauiyyedi S
TI -
Case records of the Massachusetts General Hospital. Weekly
clinicopathological exercises. Case 4-2002. A 75-year-old man with acute
renal failure five months after cystoprostatectomy and urethrectomy for
carcinoma.
SO - N Engl J Med 2002 Jan 31;346(5):353-60
6
UI - 11828774
AU - Matsuoka Y; Ishizaka K; Kobayashi T; Machida T; Oka K
TI -
[Transitional cell carcinoma of the ureter with inverted proliferation
accompanied with papillary bladder tumor: a case report]
SO - Hinyokika Kiyo 2001 Dec;47(12):861-3
AD - Department of Urology, Kanto Central Hospital.
An 85-year-old female was referred to our hospital with chief complaints
of right flank pain and gross hematuria. Ultrasonography demonstrated
right hydroureteronephrosis and a thumb head-sized solid mass in the
lower third of the right ureter. Cystoscopy revealed papillary tumors
near the right ureteral orifice. Under the preoperative diagnosis of
right ureteral tumor and bladder tumor, transurethral resection of
bladder tumor, right nephroureterectomy and partial cystectomy were
performed. The gross specimen of the ureter contained a 5 x 3 x 1 cm,
polypoid and smooth-surfaced tumor. The pathological diagnosis of the
ureteral tumor was transitional cell carcinoma with inverted
proliferation, grade 1 >> grade 2. On the other hand, the bladder tumor
was papillary transitional cell carcinoma, grade 1. This is a case in
which tumor development showed two different types.
7
UI - 11842536
AU - Okutani T; Kobayashi K; Hayashi M
TI -
[Experience of nephroureterectomy with modified "pluck" method--En bloc
removal of kidney and ureter]
SO - Nippon Hinyokika Gakkai Zasshi 2002 Jan;93(1):28-32
PURPOSE: Transurethral removal of the ureter in nephroureterectomy has
been reported by several centers as being a useful procedure. We also
have employed this procedure in selective cases, but we had several
problems in this procedure. So we tried the modified pluck
nephroureterectomy technique (En bloc removal of kidney and ureter) to
or ureteral tumor, 2 with renal cell carcinoma and 3 with benign
diseases. Standard nephrectomy is performed. After transurethral
resection of the ureteral meatus, the distal ureter is freed by blind
retroperitoneal dissection and plucked out of the bladder in continuity
with the kidney. The bladder is drainaged for 6-10 days after surgery.
RESULTS: The average time and blood loss during the operation were 247
minutes and 287 ml. No appreciable complications such as retroperitoneal
urine leakage or hemorrhage during or after the procedure were observed.
CONCLUSIONS: The modified pluck technique is useful because of its
easiness and minimal invasiveness.
8
UI - 11832714
AU - Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
TI -
Over expression of CD44V8-10 in urinary exfoliated cells as an
independent prognostic predictor in patients with urothelial cancer.
SO - J Urol 2002 Mar;167(3):1282-7
AD - Department of Urology, Kobe University School of Medicine, Kobe, Japan.
PURPOSE: CD44 is a widely expressed cell surface adhesion molecule, of
which various isoforms arise from alternative RNA splicing mechanisms.
Over expression of specific CD44 splice variants, namely CD44v8-10, is
evident in various malignant tumors and is considered to be associated
with disease progression. In this study, we investigated whether the
transcriptional level of CD44v8-10 relative to that of the standard CD44
isoform would predict the extent and prognosis of urothelial cancer.
MATERIALS AND METHODS: The CD44v8-10- to -standard CD44 ratio was
measured in the tissue (40 urothelial cancer specimens and corresponding
normal urinary tissue) and spontaneously voided urine samples of 150
patients with urothelial cancer and 50 with benign urological disease by
reverse transcriptase-polymerase chain reaction using the set of primers
capable of amplifying all CD44 splice variant isoforms. RESULTS:
Initially any CD44 variant isoforms were barely detectable in normal
urinary tissues, whereas CD44v8-10 was predominantly expressed in most
urothelial cancer specimens. Furthermore, the CD44v8-10- to -standard
CD44 ratio in urothelial cancer was closely associated with tumor
progression. We then compared the ratio in urothelial cancer tissue and
urinary exfoliated cells, and noted a linear and significant correlation
of these 2 values in the same patients. Therefore, we investigated
whether the CD44v8-10- to -standard CD44 ratio in urinary exfoliated
cells would predict the prognosis and disease progression. The mean
ratio in the urinary exfoliated cells of patients with invasive
urothelial cancer was significantly higher than in those with
superficial urothelial cancer. Of the patients with superficial bladder
cancer disease-free survival rate of those with an elevated versus a
normal ratio was significantly lower. Moreover, of the patients with
advanced urothelial carcinoma who underwent complete resection
disease-free survival of those with an elevated CD44v8-10- to -standard
CD44 ratio was significantly lower than that of patients with a normal
ratio. CONCLUSIONS: These results indicate that CD44v8-10 is strongly
expressed in tumor tissue and evident at high levels in urinary
exfoliated cells of patients with invasive versus superficial urothelial
cancer. An elevated CD44v8-10- to -standard CD44 ratio in urinary
exfoliated cells may serve as a novel prognostic predictor and indicator
of disease extent in patients with urothelial cancer.
9
UI - 11832745
AU - Fukasawa M; Kobayashi H; Matsushita K; Araki I; Takeda M
TI -
Intraperitoneal rupture of giant hydronephrosis due to ureteral cancer
accompanied by renal cell carcinoma.
SO - J Urol 2002 Mar;167(3):1393-4
AD - Department of Urology, Shimoina Red Cross Hospital, Shimoina, Japan.
10
UI - 11832751
AU - Kurokawa S; Kojima Y; Tozawa K; Hayashi Y; Sasaki S; Kohri K
TI -
Female paraurethral leiomyoma: immunohistochemical approach to the
relationship between leiomyoma and ovarian hormones.
SO - J Urol 2002 Mar;167(3):1403-4
AD - Department of Urology, Nagoya City University Medical School, Nagoya,
Japan.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home